Harmalol (hydrochloride hydrate)
(Synonyms: 骆驼蓬酚盐酸盐(二水)) 目录号 : GC49855A β-carboline alkaloid and an active metabolite of harmaline
Cas No.:6028-00-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Harmalol is a β-carboline alkaloid and an active metabolite of harmaline that has been found in P. harmala and has diverse biological activities.1,2,3,4,5 It is an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A; IC50 = 0.63 µM) and monoamine oxidase A (MAO-A; IC50 = 0.66 µM).3 It is selective for DYRK1A over Cdk1, Cdk5, CK1α1, Clk4, DYRK2, Pim-1, and GSK3β but also inhibits DYRK1B and Clk1 at 10 µM. It inhibits proliferation of H4 human glioblastoma cells (IC50s = 23.7 µM). Harmalol (0.5-12.5 µM) reduces increases in the levels of the cytochrome P450 (CYP) isoform CYP1A1 induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in HepG2 cells and prevents TCDD-induced activation of the aryl hydrocarbon receptor (AhR) in guinea pig hepatic cytosolic extracts.4 It reduces glutamate-induced cytotoxicity, cytochrome c release, caspase-3 activation, and the production of reactive oxygen species (ROS) in PC12 cells when used at a concentration of 25 µM.5 This product is also available as an analytical reference standard .
1.Brierley, D.I., and Davidson, C.Developments in harmine pharmacology - implications for ayahuasca use and drug-dependence treatmentProg. Neuropsychopharmacol. Biol. Psychiatry39(2)263-272(2012) 2.Nikam, T.D., Nitnaware, K.M., and Ahire, M.L.Alkaloids derived from tryptophan: Harmine and related alkaloidsNatural products. Phytochemistry, botany and metabolism of alkaloids, phenolics and terpenes553-574(2013) 3.Tarpley, M., Oladapo, H.O., Strepay, D., et al.Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studiesEur. J. Pharm. Sci.162105821(2021) 4.El Gendy, M.A.M., Soshilov, A.A., Denison, M.S., et al.Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanismsFood Chem. Toxicol.50(2)353-362(2012) 5.Han, E.S., and Lee, C.S.Inhibition of glutamate-induced change in mitochondrial membrane permeability in PC12 cells by 1-methylated β-carbolinesBiomol. Ther. (Seoul)11(2)112-118(2003)
Cas No. | 6028-00-8 | SDF | Download SDF |
别名 | 骆驼蓬酚盐酸盐(二水) | ||
Canonical SMILES | OC1=CC=C2C(NC3=C2CCN=C3C)=C1.Cl.O.O | ||
分子式 | C12H12N2O • HCl [2H2O] | 分子量 | 272.7 |
溶解度 | DMF: 10 mg/ml,DMSO: 1 mg/ml,Ethanol: 2 mg/ml,PBS (pH 7.2): insol | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.667 mL | 18.3352 mL | 36.6703 mL |
5 mM | 0.7334 mL | 3.667 mL | 7.3341 mL |
10 mM | 0.3667 mL | 1.8335 mL | 3.667 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。